
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved FDF
Recipient : Kashiv BioSciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Kashiv and JAMP Launch PEXEGRA and FILRA Biosimilars in Canada
Details : Pexegra (pegfilgrastim) biosimilar is a leukocyte growth factor indicated for the treatment of febrile neutropenia.
Product Name : Pexegra
Product Type : Protein
Upfront Cash : Inapplicable
September 24, 2025
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : Kashiv BioSciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, it reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. It is approved by Health Canada for the treatment of type 2 diabetes.
Product Name : Forxiga-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
